Publications by Epividian Scientists and Collaborators

 

Abstracts and Posters


Hsu R, Brunet L, Fusco J, Vannappagari V, Clark A, Lackey P, Pierone G, Fusco G. Fostemsavir use in the OPERA cohort: immunologic and virologic response.  19th European AIDS Conference (EACS). Warsaw, Poland, October 18-21, 2023.

Sension M, Hsu RK, Fusco JS, Brunet L, Cochran Q, Sridhar G, Vannappagari V, van Wyk J, Wohlfeiler MB, Fusco GP. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA® Cohort. IDWeek. Boston, MA, USA; October 11-15, 2023

Brunet L, Jonsson Funk ML, Cash RB, Fusco JS, Walder L, Laws A, Wohlfeiler M, Sension M, Fusco GP. Virologic effectiveness of ibalizumab clinical trial experience compared to real-world clinical care without ibalizumab in the OPERA® Cohort. ACTHIV. Phoenix, AZ, USA, May 4-6, 2023 Download PDF >

Hsu RK, Palmieri Weber R, Fusco JS, Dunbar MS, Gruber J, Marongiu A, Lackey PC, Pierone GJ, Fusco GP. Demographic and Clinical Characteristics of People in OPERA® with HIV and Heavy Treatment Experience. Phoenix, AZ, USA, May 4-6, 2023 Download PDF >

Sension M, Brunet L, Hsu RK, Mounzer K, Fusco JS, Whiteside YO, Arduino JM, Kolobova I, Fusco GP. Patterns of Doravirine Use in a US Cohort. HIV Glasgow 2022. Glasgow, United Kingdom; October 23-26, 2022

Pierone G, Fusco J, Brunet L, Vannappagari V, Sarkar S, Henegar C, van Wyk J, Zolopa A, Fusco G. Real world use of dolutegravir/lamivudine in treatment naïve people living with HIV during the COVID pandemic. HIV Glasgow 2022. Glasgow, United Kingdom; October 23-26, 2022

Wohlfeiler M, Palmieri Weber R, Brunet L, Siddiqui J, Harbour M, Phillips A, Hayward B, Fusco J, Hsu R, Fusco G. HIV-Associated Wasting in the Era of Weight Gain. HIV Glasgow 2022. Glasgow, United Kingdom; October 23-26, 2022

Wohlfeiler M, Pamieri Weber R, Brunet L, Siddiqui J, Harbour M, Phillips A, Hayward B, Fusco J, Hsu R, Fusco G. Comparison of HIV-Associated Wasting Definitions in the OPERA Cohort. In HIV Glasgow 2022. Glasgow, United Kingdom; October 23-26, 2022

Hsu RK, Brunet L, Fusco JS, et al. Durability and effectiveness of fostemsavir in heavily treatment-experienced people with HIV. Presented at: IDWeek, October 19-23, 2022; Washington, DC, USA. [Rapid Fire Poster Session]

Pierone G, Fusco JS, Brunet L, et al. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens. Presented at: IDWeek, October 19-23, 2022; Washington, DC, USA. [Rapid Fire Poster Session]

Wohlfeiler MB, Palmieri Weber R, Brunet L, et al. Association between Incident HIV-Associated Wasting/Low Weight and All-Cause Mortality in the OPERA® Cohort. Presented at: IDWeek, October 19-23, 2022; Washington, DC, USA

Hsu RK, Brunet L, Fusco JS. Guiding COVID-19 Booster Vaccinations by COVID-19 Quantitative Spike Ig Antibody Titers Regardless of HIV Status, Immunosuppression, and Age. Presented at: IDWeek, October 19-23, 2022; Washington, DC, USA

Mounzer K, Brunet L, Fusco J, et al. Advanced HIV infection in the US: immune response to ART initiation. Paper presented at: 24th International AIDS Conference 2022; Montreal, Canada Download PDF >

Pierone G, Brunet L, Fusco JS, et al. Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care. Presented at: 24th International AIDS Conference 2022; Montreal, Canada Download PDF >

Wohlfeiler MB, Palmieri Weber R, Brunet L, et al. Predictors of Incident HIV-Associated Wasting and Low Weight in the OPERA® Cohort, 2016-2021. Presented at: ACTHIV 2022; Denver, CO, USA Download PDF >

Sension MG, Hsu RK, Fusco JS, et al. Early Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US. Presented at: ACTHIV 2022; Denver, CO, USA

Wohlfeiler M, Weber RP, Brunet L, et al. Positive Pathways: Implementation Trial for HIV Retention in Care [908]. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2022; Virtual Meeting

Pierone GJ, Fusco JS, Brunet L, et al. The Impact of the COVID-19 Pandemic on Clinical Follow-up, Monitoring and Regimen Discontinuation for People Living with HIV in the US. Presented at: IDWeek 2021; Virtual Event

Mounzer K, Brunet L, Fusco J, et al. Effectiveness of recommended three-drug regimens for treating advanced HIV infection [Abstract 406]. Presented at: CROI 2021; Virtual Meeting

Leonard M, Palmieri Weber R, Brunet L, et al. Clinical Decision Support System Alerts for HIV Retention in Care-A Pilot Implementation Research Study. Presented at: IDWeek 2020; Virtual Meeting Download PDF >

Pierone G, Schulman K, Fusco J, et al. Characteristics of Early Adopters of a Two-Drug Regimen (Dolutegravir/Lamivudine) for Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) in a Real-World Setting. Presented at: ACTHIV 2020; Virtual Meeting.

Hsu R, Fusco J, Henegar C, et al. Clinical outcomes of heavily treatment experienced individuals in the OPERA Cohort [PEB0234]. Presented at: The 23rd International AIDS Conference (AIDS 2020) 2020; Virtual Meeting

Mounzer K, Brunet L, Wyatt C, et al. To Dose-Adjust or Not to Dose-Adjust: 3TC Dose in Renal Impairment. Presented at: The 23rd International AIDS Conference (AIDS 2020) 2020; Virtual Meeting. San Francisco

Mounzer K, Brunet L, Wyatt C, et al. To Dose-Adjust or Not to Dose-Adjust: 3TC Dose in Renal Impairment. Paper presented at: 24th International Workshop on HIV and Hepatitis Observational Database (IWHOD) 2020; Meeting Canceled (COVID-19)

Hsu R, Brunet L, Fusco J, Fusco G. EASL Biomarkers Differ in Predicting NAFLD, NASH, & Fibrosis in HIV(+)/(-) Individuals. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2020; Boston, MA, USA Download PDF >

Pierone G, Schulman KL, Fusco J, et al. 2-Drug Regimen Comparable to 3-Drug Regimens up to 18 Months in a Real-World Setting. Presented at: CROI 2020; Boston, MA, USA Download PDF >

Russo M, Fusco J, Dieterich D, Brunet L, Fusco G. Outcomes in 960 individuals with triple infection with HIV, chronic hepatitis B, and chronic hepatitis C. Presented at: AASLD 2019; Boston, MA, USA Download PDF >

Dieterich D, Fusco J, Russo M, Brunet L, Fusco G. Loss of surface antigen in HIV/HBV co-infected individuals. Presented at: AASLD 2019; Boston, MA, USA Download PDF >

Mallon P, Brunet L, Fusco J, et al. Changes in LDL After Switch from TDF to TAF in the U.S. [PE2/44]. Presented at: 17th European AIDS Conference (EACS 2019); 6-9 November 2019, 2019; Basel, Switzerland.

Hsu R, Brunet L, Mounzer K, et al. Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV [PE2/32]. Presented at: European AIDS Conference (EACS) 2019; Basel, Switzerland Download PDF >

Pierone G, Schulman KL, Fusco J, et al. Comparison of a Two-Drug Regimen (Dolutegravir/Rilpivirine) to Standard Three-Drug Regimens in Virologically Suppressed, Treatment Experienced Individuals in the Real World [PE2/37]. Presented at: 17th European AIDS Conference (EACS 2019) 2019; Basel, Switzerland

Wohlfeiler MB, Schulman KL, Fusco J, et al. Virologic Failure In ART-Naïve Patients Initiating on a Dolutegravir- or Elvitegravir-Based Regimen. Presented at: IDWeek 2019; Washington, DC, USA Download PDF >

Hsu R, Brunet L, Fusco J, et al. Risk of type-2 diabetes mellitus after initiating integrase and protease inhibitors in individuals living with HIV in the United States [341]. Paper presented at: IDWeek 2019; Washington, DC, USA Download PDF >

Mallon P, Brunet L, Fusco J, et al. Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV [337]. Presented at: IDWeek 2019; Washington, DC, USA. Download PDF >

Pierone G, Schulman KL, Fusco J, et al. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States [2483]. Presented at: IDWeek 2019; Washington, DC, USA Download PDF >

Mounzer K, Fusco J, Hsu R, et al. TDF/FTC Pre-Exposure Prophylaxis (PrEP) from 2012 to 2018 in the OPERA Cohort. Presented at: 10th IAS Conference on HIV Science 2019; Mexico City, Mexico. Download PDF >

Mounzer K, Brunet L, Fusco J, et al. Gastrointestinal Disorders Following Initiation of Dolutegravir, Elvitegravir, Raltegravir or Darunavir. Presented at: 10th IAS Conference on HIV Science 2019; Mexico City, Mexico Download PDF >

Hsu R, Brunet L, Fusco J, et al. Renal Function with Dolutegravir, Elvitegravir/Cobicistat, Raltegravir or Darunavir. Paper presented at: 10th IAS Conference on HIV Science 2019; Mexico City, Mexico Download PDF >

Mills A, Schulman K, Fusco J, et al. Virologic Outcomes among Treatment-Naïve HIV+ Patients Initiating Common First Antiretroviral Therapy Core Agents in the OPERA Observational Database. Presented at: ISPOR 2019; New Orleans, LA, USA Download PDF >

Brunet L, Hsu R, Mounzer K, et al. An assessment of the impact of inhibition of tubular secretion of creatinine on the study of renal function. Presented at: 23rd International Workshop on HIV and Hepatitis Observational Databases (IWHOD) 2019; Athens, Greece

Fusco J, Brunet L, Lackey P, Wohlfeiler M, Fusco G. An illustration of the impact of virologic failure definitions in clinical cohorts. Presented at: 23rd International Workshop on HIV and Hepatitis Observational Databases (IWHOD) 2019; Athens, Greece

Pierone G, Schulman KL, Fusco J, et al. Characteristics of Early Adopters of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of Human Immunodeficiency Virus Type 1 in the United States. Presented at: AMCP Managed Care & Specialty Pharmacy Annual Meeting 2019; San Diego, CA, USA Download PDF >

Mallon P, Brunet L, Fusco J, et al. Changes in Lipids After a Direct Switch from TDF to TAF [0652]. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2019; Seattle, WA Download PDF >

Lackey P, Schulman K, Fusco J, Arduino J, Prajapati G, Fusco G. Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States [555]. Presented at: IDWeek 2018; San Francisco, CA, USA Download PDF >

Wohlfeiler M, Mounzer K, Brunet L, et al. A Comprehensive Assessment of Hepatobiliary Disorders in HIV-Infected Patients Treated with Dolutegravir, Elvitegravir, Raltegravir or Darunavir in the OPERA Database. Presented at: 22nd International AIDS Conference 2018; Amsterdam, the Netherlands Download PDF >

Dieterich D, Brunet L, Fusco J, et al. Clinical Effectiveness of Guideline-Recommended Antiretroviral Therapy Core Agents in HIV/HCV Co-infected Patients in the OPERA Observational Database. Presented at: 22nd International AIDS Conference 2018; Amsterdam, the Netherlands

Hsu R, Henegar C, Fusco J, et al. Identifying Heavily Treatment-Experienced Patients in the OPERA Cohort [THPEB044]. Presented at: 22nd AIDS International Conference; 2018; Amsterdam, the Netherlands Download PDF >

Mills A, Brunet L, Fusco J, et al. Virologic Outcomes Among Treatment Naïve HIV+ Patients Initiating Common First Antiretroviral Therapy Core Agents in the OPERA Observational Database [PEB039]. Presented at: 22nd International AIDS Conference; 2018; Amsterdam, the Netherlands Download PDF >

Heglar R, Mood R, Priest J, Schulman K, Fusco G. Benchmarking HIV Quality Measures in the US OPERA HIV Cohort. Presented at: ISPOR 2018; Baltimore, MD, USA Download PDF >

Dieterich D, Brunet L, Fusco J, et al. Clinical Effectiveness of Guideline-Recommended Antiretroviral Therapy Core Agents in HIV/HCV Coinfected Patients in the OPERA Observational Database. Paper presented at: 22nd International Workshop on HIV and Hepatitis Observational Databases (IWHOD) 2018; Fuengirola, Spain

Mills A, Schulman K, Fusco J, et al. Validation of a chronic kidney disease risk score in HIV+ Patients in the U.S. [730]. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 04-07 MAR 2018, 2018; Boston, MA Download PDF >

Pierone G, Henegar C, Fusco J, et al. Virologic Response To 2-Drug ART Regimens Among Treatment-Experienced HIV+ Patients. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2018; Boston, MA USA

Henegar C, Beckerman R, Fusco J. The impact of HIV coinfection on hepatitis C virus (HCV) treatment initiation. Presented at: International Conference on Pharmacoepidemiology 2017; Montreal, Canada Download PDF >

Mounzer K, Hsu R, Henegar C, et al. Uptake of HLA-B*5701 screening and its impact on clinically suspected hypersensitivity reaction to abacavir in the OPERA observational database [A-854-0101-0466]. Presented at: 9th IAS Conference on HIV Science 2017; Paris, France Download PDF >

Carpio F, Henegar C, Fusco J, et al. Initial regimen duration in female patients taking integrase strand transfer inhibitors (INSTI) in the OPERA observational database [A-854-0129-02932]. Presented at: 9th IAS Conference on HIV Science 2017; Paris, France Download PDF >

Hsu R, Fusco J, Henegar C, et al. Psychiatric disorders observed in HIV+ patients using 6 common 3rd agents in OPERA [664]. Presented at: Conference on Retroviruses and Opportunistic Infections 2017; Seattle, WA, USA Download PDF >

Dieterich D, Henegar C, Fusco J, Lackey P. Hepatitis C virus testing, prevalence, and treatment in a large cohort of treatment-naïve, HIV-positive individuals. Presented at: AASLD The Liver Meeting 2016; Boston, MA, USA Download PDF >

Melikian G, Lackey P, Henegar C, Zelt S, D'Amico R, Carpio F. Syphilis, race, baseline labs, and antiretroviral regimen predict virologic success in naïve HIV+ adolescents and young adults [1512]. Presented at: Infectious Diseases Week 2016; New Orleans, LA, USA Download PDF >

Mills A, Fusco J, Schulman KL, et al. The impact of antiretroviral tablet burden and polypharmacy on viral suppression in treatment-naïve patients [1512]. Presented at: Infectious Diseases Week 2016; New Orleans, LA, USA Download PDF >

Melikian G, Fusco J, Schulman K, et al. Variability in population characteristics among HIV+ ART-naïve patients initiating on single tablet regimens [1517]. Presented at: Infectious Diseases Week 2016; New Orleans, LA, USA Download PDF >

Wohlfeiler M, Henegar C, Schulman K, et al. Predictors of virologic success in an older ART naïve HIV population [2127]. Presented at: Infectious Diseases Week 2016; New Orleans, LA, USA Download PDF >

Dieterich D, Fusco J, Henegar C, et al. HIV/Hepatitis C co-infected patients are significantly more complex to manage than HIV mono-infected patients in a large cohort of treatment-naïve, HIV-positive individuals [P260]. Presented at: HIV Drug Therapy Glasgow Meeting 2016; Glasgow, UK Download PDF >

Lackey P, Schulman K, Henegar C, D'Amico R, Zelt S, Fusco G. Trends in HIV antiretroviral tablet burden in treatment-naïve patients in the United States. Presented at: The Academy of Managed Care Pharmacy (AMCP) Nexus Meeting 2016; National Harbor, MD, USA. Silver Award Recipient Download PDF >

Wohlfeiler M, Carpio F, Lackey P, et al. INSTI In-Class Switching on Continued Viral Suppression in the OPERA Cohort [953]. Presented at: Conference on Retroviruses and Opportunistic Infections 2016; Boston, MA, USA Download PDF >

Lackey P, Mills A, Carpio F, et al. Virologic effectiveness of abacavir/lamivudine with darunavir versus other protease inhibitors in treatment-experienced HIV-infected patients in clinical practice [1086]. Presented at: Infectious Diseases Week 2015; San Diego, CA, USA Download PDF >

DeJesus E, Pierone G, Lackey P, et al. Utilization patterns of raltegravir within the OPERA database. Presented at: 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) 2009; Philadelphia, PA, USA

Fultz SL, Chang CCH, Skanderson M, Butt AA, Rigsby MO, Fusco GP, Dieterich DT, Becker SL, Simberkoff M, Rabeneck L, Rodriguez-Barradas M, Justice AC. Survival in patients coinfected with HIV and Hepatitis C: Is there a CD4 threshold. Poster. XV International AIDS Conference, July 2004, Bangkok, Thailand

Mera R, Most B, Balu RB, Fusco JS. Dynamics of immunologic decline and virological rebound during treatment interruption in chronic HIV disease. 4593. Poster. XV International Aids Conference, July 2004, Bangkok, Thailand

Gibbons DC, Baker RK, Bartlett JA, Cutrell AG, Eron JJ, Fusco GP, Fusco JS, Gallant JE, Mole L, Moore RD, Nordstrom BL, Rosenberg DM, Walker AM, White AD, Wood KC. Use of novel methodology for a risk management program examining risk of abacavir hypersensitivity reaction, rechallenge reaction, hospitalization, and death. Poster. 19th International Conference on Pharmacoepidemiology and the 1st International Conference on Therapeutic Risk Management. August 2003, Philadelphia, PA

Raffanti SR, Fusco JS, Becker SL, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, Mangialardi WJ, Fusco GP. Moderate viremia and HIV disease progression. Poster. LB35, International AIDS Society Conference. July 2003, Paris, France.

Balu RB, Raffanti s, Wesolowski L, Justice AC, Fusco JS, Mangialardi W, Fusco GP. Sex specific differences in liver function and disease progression. Poster. 7th International Workshop on HIV Databases. March 2003, Fiuggi, Italy

Paulsen D, Florance A, Liao Q, Boulme R, Shaefer M, Fusco GP, Ross L. Comparison of HIV-1 protease inhibitor susceptibility results in viremic protease inhibitor(PI)-experienced patient samples analyzed by phenotyping and by five resistance algorithms. Poster. 6th International HIV Drug Resistance Workshop. July 2002, Seville, Spain

Chene C, May M, Costagliola D, d’Arminio Monforte A, Junghans C, de Wolf F, Lundgren JD, Fusco GP, Miller V, Leport C, Dabis F, Hogg RS, Phillips AN, Gill MJ, Salzberger B, Sterne JAC, Egger M. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. Poster. XIV International AIDS Conference. July 2002, Barcelona, Spain

Dieterich DT, Becker SL, Fusco JS, Balu RB, Most BM, Stern JAC, Lanes S, Fusco GP. Low incidence of grade III/IV hepatotoxicity in first HAART: observations from 1100 patients followed for 1 year. Poster. 4534. XIV International AIDS Conference. July 2002, Barcelona, Spain.

Fusco GP, Justice AC, Becker SL, Raffanti SP, Coll-Erickson P, Fusco JS. Strategies for obtaining consistent diagnoses for cause of death in an HIV observational cohort study. Poster. 5584. XIV International AIDS Conference. July 2002, Barcelona, Spain

Ross L, Paulsen D, Liao Q, Fusco GP, Shaefer M, St. Clair M. Genotypic and phenotypic resistance patterns to Lopinavir and Amprenavir in viremic protease inhibitor-experienced patients. Poster. 4th International HIV Workshop on Management of Treatment-Experienced Patients. April 2001, Chicago, IL

Sterne JAS, Grabar S, d'Arminio Monforte A, Rickenbach M, de Wolf F, Lundgren JD, Fusco JS, Miller V, Raffi F, Dabis F, Hogg RS, Lampe F, Gill MJ, Salzberger B, May M, Egger M. What is the prognostic value of baseline CD4 cell count and viral load six months after initiating potent antiretroviral therapy? ART cohort collaboration. Poster. XIV International AIDS Conference. July 2002, Barcelona, Spain

Becker SL, Scarsella AJ, Chulay J, Fusco GP. Efficacy of amprenavir-containing HAART regimens in protease inhibitor-experience patients. Poster. 39th Annual Meeting of the Infectious Disease Society of America (IDSA). October 2001, San Francisco, CA

Becker SL, Dieterich DT, Fusco GP. Clinical experience of lopinavir / ritonavir (LPV/RTV) following amprenavir (APV) use. Poster. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. October 2001, Athens, Greece.

Braun JF, Fusco JS, Justice AC, Most BM, Fusco GP. Predictors of virologic and immunologic success post treatment interruption (TI) in patients with chronic HIV infection. Poster. 1909. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December 15-19, 2001, Chicago, IL

Becker SL, Fusco JS, Justice AC, Hansen NI, Fusco GP. Comparison of protease inhibitor (PI)-containing and non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing HAART in HIV patients naïve to antiretrovirals. Poster 230. International AIDS Society Conference on HIV Pathogenesis and Treatment. July 8 –11, 2001, Buenos Aires, Argentina

Paulsen D, Shaefer M, Fusco GP, Ross L. Cross-resistance to amprenavir and lopinavir in HIV-1 from subjects failing protease inhibitor therapies; mutations in HIV-1 with resistance to one or both drugs. Poster. 5th International Workshop on HIV Drug Resistance & Treatment Strategies. June 4-8, 2001, Scottsdale, AZ

Justice AC, Fusco JS, Becker SL, Raffanti SR, Fusco GP. Strategies for obtaining consistent diagnoses for cause of death in an observational cohort study. Poster. 5th International Workshop on HIV Observational Databases. April 2001, Monte Carlo, Monaco

Scarsella AJ, Dieterich DT, Graham NMH, Fusco GP, Sherrill BH, Fusco JS, Hansen NI, Becker SL. Predictors of lipodystrophy in HIV-infected patients. Poster. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2000, Toronto, Ontario

Becker SL, Scarsella A, Graham N, Fusco GP, Sherrill B, Fusco JS, Hansen N. Efficacy of amprenavir-containing HAART regimens in protease inhibitor-experienced patients. Poster. 38th Annual Meeting of the Infectious Disease Society of America (IDSA). September 2000, New Orleans, LA

Justice AC, Stein DS, Fusco GP, Sherrill BH, Danehower SC, Fusco JS, Hansen NI, Becker SL. Comparative effects on clinical progression of d4T vs. ZDV containing regimens. Poster. 7th Conference on Retroviruses and Opportunistic Infections. January-February 2000, San Francisco, CA

Justice A, Stein DS, Fusco GP, Sherrill B, Danehower S, Fusco J, Hansen N, Becker S. Relationships among antiretroviral therapies (ART) and clinical outcomes. Poster. 7th Conference on Retroviruses and Opportunistic Infections. January-February 2000, San Francisco, CA

Raffanti SR, Fusco GP, Mangialardi WJ, Fusco JS, Hansen NI, Sherrill BH, Igboko EF. The effect of virologic control on rates of disease progression. Poster. 37th Annual Meeting of the Infectious Disease Society of America (IDSA). November 1999, Philadelphia, PA